Memory Alzheimer’s Disease Candidate Shows Cognitive Benefit In Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm expects Roche to make a decision on an option for the nicotinic alpha-7 receptor partial agonist in the first half of 2008.
You may also be interested in...
Roche Cash Infusion Saves Partnered Memory Program, Allows Expanded Phase II Study
Memory halves its workforce to find funds for the cognitive impairment associated with schizophrenia program.
Roche Cash Infusion Saves Partnered Memory Program, Allows Expanded Phase II Study
Memory halves its workforce to find funds for the cognitive impairment associated with schizophrenia program.
Roche Licenses Memory’s Lead CNS Compound
Swiss firm exercises option on nicotinic alpha-7 receptor agonist, gives Memory needed cash infusion.